Paper Details

  1. Home
  2. Paper Details

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).

Author: AmadoriS, HalkesC J M, KarraschM, MarieJ P, MeertL, MeloniG, MuusP, RapionJ, SuciuS, VignettiM, WillemzeR, de WitteT

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examined the safety and effectiveness of clofarabine, a chemotherapy drug, in combination with other chemotherapy drugs for treating leukemia and myelodysplastic syndrome. The study found that a dose of 5 × 10 mg/m(2)/day was well-tolerated and effective, making it a potential treatment option for these conditions.
Paper Details　
Original Abstract of the Article :
This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome. In this phase I trial, 25 patients (medi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-014-2056-6

データ提供：米国国立医学図書館（NLM）

Clofarabine: A New Weapon in the Fight Against Leukemia

The world of cancer treatment is like a vast desert landscape, filled with challenges and opportunities for new discoveries. This research explores the potential of clofarabine, a promising new drug, in combination with standard chemotherapy for treating acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS). The researchers are like intrepid explorers, seeking to find the right dose and combination of drugs to effectively combat these challenging cancers.

Finding the Right Dose: A Balancing Act

This study is like a carefully crafted map, guiding researchers to the optimal dose of clofarabine. They conducted a Phase I trial, gradually increasing the dose of clofarabine while closely monitoring patient safety and response. They discovered that 5 × 10 mg/m(2)/day of clofarabine in combination with the standard regimen produced the best results, with minimal side effects. It's like finding the perfect oasis in the desert: the right dose and combination of treatments can lead to significant improvement in patients' lives.

Hope on the Horizon: A New Era for Cancer Treatment

The study's findings suggest that clofarabine holds promise as a valuable addition to the treatment arsenal for AML and HR-MDS. The results are like a beacon of hope in a vast desert, offering new possibilities for better treatment outcomes.

Dr. Camel's Conclusion

This research offers a glimmer of hope in the desert of cancer treatment. The careful exploration of clofarabine's potential, guided by a meticulous trial, has led to promising results. It's a reminder that, with dedication and careful research, we can find new ways to fight against these challenging diseases.

Date :
  1. Date Completed 2014-06-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24682421

DOI: Digital Object Identifier

10.1007/s00277-014-2056-6

Related Literature

Article Analysis
・Effects of clofarabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.